These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34232140)

  • 1. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms.
    Gleitz HFE; Benabid A; Schneider RK
    Curr Opin Hematol; 2021 Sep; 28(5):364-371. PubMed ID: 34232140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
    Gleitz HFE; Dugourd AJF; Leimkühler NB; Snoeren IAM; Fuchs SNR; Menzel S; Ziegler S; Kröger N; Triviai I; Büsche G; Kreipe H; Banjanin B; Pritchard JE; Hoogenboezem R; Bindels EM; Schumacher N; Rose-John S; Elf S; Saez-Rodriguez J; Kramann R; Schneider RK
    Blood; 2020 Oct; 136(18):2051-2064. PubMed ID: 32726410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
    Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
    PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.
    Gleitz HF; Kramann R; Schneider RK
    J Pathol; 2018 Jun; 245(2):138-146. PubMed ID: 29570794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
    Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
    Virchows Arch; 2024 May; 484(5):837-845. PubMed ID: 38602559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of inflammation in the biology of myeloproliferative neoplasms.
    Koschmieder S; Chatain N
    Blood Rev; 2020 Jul; 42():100711. PubMed ID: 32505517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanobiology and Primary Cilium in the Pathophysiology of Bone Marrow Myeloproliferative Diseases.
    Tiberio F; Coda ARD; Tosi DD; Luzi D; Polito L; Liso A; Lattanzi W
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
    Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
    Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
    Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche.
    Yao JC; Oetjen KA; Wang T; Xu H; Abou-Ezzi G; Krambs JR; Uttarwar S; Duncavage EJ; Link DC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35439167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
    Li R; Colombo M; Wang G; Rodriguez-Romera A; Benlabiod C; Jooss NJ; O'Sullivan J; Brierley CK; Clark SA; Pérez Sáez JM; Fernández PA; Schoof EM; Porse B; Meng Y; Khan AO; Wen S; Dong P; Zhou W; Sousos N; Murphy L; Clarke M; Olijnik AA; Wong ZC; Karali CS; Sirinukunwattana K; Ryou H; Norfo R; Cheng Q; Carrelha J; Ren Z; Thongjuea S; Rathinam VA; Krishnan A; Royston D; Rabinovich GA; Mead AJ; Psaila B
    Sci Transl Med; 2024 Oct; 16(768):eadj7552. PubMed ID: 39383242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
    Nagao T; Yonekura S
    Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
    [No Abstract]   [Full Text] [Related]  

  • 19. Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms.
    Herlihy N; Harrison CN; McLornan DP
    Haematologica; 2019 Apr; 104(4):639-641. PubMed ID: 30930333
    [No Abstract]   [Full Text] [Related]  

  • 20. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.